Side-by-side · Research reference

EpitalonvsFOXO4-DRI

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED8/37 cited

BAnimal-StrongHUMAN-REVIEWED12/45 cited

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

FOXO4-DRI

Senolytic Peptide · D-Retro-Inverso

p53-TADMolecular targetBourgeois 2025

Pre-clinicalDevelopment stage

SQRoute (animal)

SQ · Animal models only

01Mechanism of Action

Parameter

Epitalon

FOXO4-DRI

Primary target

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

FOXO4-p53 protein complex in senescent cellsBourgeois 2025 Tripathi 2021

Pathway

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells

Downstream effect

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021 Alameen 2026

Feedback intact?

—

Origin

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance

Antibody development

—

02Dosage Protocols

Parameter

Epitalon

FOXO4-DRI

Standard dose

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

—

Frequency

Once daily during a cycle

—

Lower / starter dose

2.5 mg / day

—

Evidence basis

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Animal / mechanistic

Duration

10–20 day cycles, 1–2× per year

Weeks to months (animal studies)

Senescent cell clearance observed within weeks.

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep preferred (pineal alignment)

—

Half-life

Hours (estimated)

—

Animal dose (mouse)

—

5 mg/kg

SQ injection, aged mouse model (testosterone restoration).

Frequency (animal)

—

Variable — single or intermittent dosing

Protocol-dependent; no standardised regimen.

Human equivalent (theoretical)

—

~0.4 mg/kg (28 mg / 70 kg adult)

Extrapolated using allometric scaling; no clinical validation.

Route

—

SQ (animal)

No human route established.

Clinical status

—

No human trials completed

04Side Effects & Safety

Parameter

Epitalon

FOXO4-DRI

Injection site reaction

Mild irritation

—

Sleep architecture

Improved subjective sleep quality (anecdotal)

—

Cancer risk

Theoretical via telomerase activation in pre-malignant cells

—

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid

—

Antibody formation

Not reported

—

Pulmonary hypertension risk

—

Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023

Context-dependent toxicity

—

Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023

Off-target apoptosis

—

Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)

Immune perturbation

—

Senescent cells contribute to immune surveillance; clearance effects unknown

Human safety unknown

—

No clinical trials — toxicity profile in humans not established

Absolute Contraindications

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

FOXO4-DRI

·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
·Pregnancy / lactation (no safety data)

Relative Contraindications

Epitalon

·Family history of cancer

FOXO4-DRI

·Active malignancy (senescence as tumour suppressor mechanism)
·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)

05Administration Protocol

Parameter

Epitalon

FOXO4-DRI

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

Subcutaneous injection used in rodent models. No human administration protocol exists.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.

3. Timing

Pre-sleep preferred to align with pineal axis.

Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.

5. Needle

29–31G, 4–8 mm insulin syringe.

Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.